When immunoassay techniques are used for the measurement of protein concentrations, antigen-antibody reaction products -a two components metric system -are measured in immunocomplexes representing the quantities as well as the immunoreactivity qualities of both assay partners. The relationship between the measured signal size and the expected value result depends on many immunochemical and non immunochemical influences and effects. Especially variabilities in the molecular structure of proteins influence the signal size differently which can lead to wrong results.
Introduction
The determination of human proteins is usually performed by immunoassay techniques, today mainly by automated systems using the light scattering of immunocomplexes as a signal generator. It means: protein concentrations are measured by comparing antigen (Ag)-antibody (Ab) reaction products for a reference protein in standard preparations with those for the analyte protein in specimens. The immunometric measurement principle is a two components system on the contrary to the one component measurement system like weighmg. This difference makes standardization measures complex and the understanding difficult. In some cases the correlation of the values obtained from method to method is quite low, in other cases the correlation is acceptable but the absolute values can be rather different. The early introduction of International Reference Preparations (WHO; 1) had not succeeded in the worldwide standardization expected for the protein analysis, because those materials were not suitable for all techniques. The establisment of the new Certified Reference Material [CRM 470 (2) Nevertheless, there have further important and till yet neglected aspects and effects to be considered which can influence the signal sizes of measurements and which can lead to wrong evaluations of value results and with it to wrong clinical interpretations. Measurement signal size versus value result
1.1.
Ag -Ab reaction product At first, it has to be realized that the common mental assumption ''the result of an immunoassay measurement is identical with the expected protein concentration" is abridged, is not true (6) .
A measurement result means a signal size (diameter for RID, voltage in "bit" for immunonephelometfy, optical density for turbidimetry) and not a value result in the dimension g/l or IU/ml. Immunoassays measure the Ag -Ab reaction products as immunocomplexes or immunoprecipitates dependent on the time interval. a) beside the quantity of the Ag (the target part needed for the clinical application) also the second reaction partner Ab is measured in the immuncomplexes.
b) furthermore the measurement signal size is not only influenced by the proportionality of both quantities Ag and Ab, but also by qualitative effects, that means by the reciprocal immunoreactivity or reaction qualitv of both assay partners.
1.2.
The immunochemical property / immunoreaction quality of the Ag depends on the molecular structure of the protein and is not constant in each case, something, which is often uncertain or unknown for the analyst. For the Ag the immunoreactivity is defined by the possibly present and/or available number of the epitopes (Ag-determinants) and their relationship , at least by the reacting ones in the actual measurement.
The immunoreactivity i.e. reaction quality of the Ab is defined by the number and relationship
-it means by the population -of monoclonal antibodies (MAB's) in the antiserum used as reagent representing the possible, but not always available and/or assailable epitopes. The affinity respectively avidity of antisera is resulting from these properties. 
Conclusion
Recommendations for a fbrther standardization of protein measurement can be given:
Physiochemical and physiological properties representing the immunoreactivities of proteins must be characterized and known, to obtain exact analysis results by immunoassay techniques. If the immunoreactivities of proteins in standard preparations and specimens are identical then the correlation for two immunoassay techniques will be acceptable (slope near to 1, low midrange). If the correlation is rather good, but the absolute concentration differs (slope >/< 1) this means that certain properties of the proteins have a different influence on both measurement principles.
The use of antibodies containing reagents is not sufficiently certified; this deficit must be compensated. For the identification of an analyte an antiserum used as reagent should represent possibly many / all epitopes of an Ag. For the auantitation of an analyte the standardization is easier if the antiserum used as reagent represents only a few epitopes of the Ag, in extreme cases the aim of standardization can be obtained if only one MAB recognizing a stable, always present representative epitope is used.
A standardized comparison method should not be influenced by non-immunochemical effects (matrix effects, interfering substances). Indeed it has to recognize / measure only the pure AgAb reaction product.
The same alteration of the Ag -immunoreactivity (increase) must not registered by the same kind of alteration of the signal size / value result (increase) using different immunoassays (and vice versa): better reactivity in RID means lower signal / lower value; better reactivity in immunonephelometry means higher signal / higher value
The reliability of an analytical process can be only well assessed if the internal quality control material contains proteins with absolutely stable molecular structure. The values should be system assigned ones.
Values obtained by a standardized comparison method should be preferred for external quality control materials and not consensus values resulting from measurements obtained by using many different assays.
It is not the immunoreactivity size of analytes, but their mass value results per volume unit what is representative for the clinical relevance of proteins and important to apply the proteins for certain diagnostic purposes.
